Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the recipient of a large increase in short interest in October. As of October 31st, there was short interest totalling 44,200 shares, an increase of 9.4% from the October 15th total of 40,400 shares. Based on an average trading volume of 31,500 shares, the short-interest ratio is currently 1.4 days.
Hedge Funds Weigh In On Entera Bio
A number of hedge funds have recently modified their holdings of the stock. Virtu Financial LLC bought a new stake in Entera Bio in the first quarter valued at $37,000. Signature Estate & Investment Advisors LLC bought a new stake in shares of Entera Bio in the 3rd quarter worth about $90,000. Finally, Parkman Healthcare Partners LLC grew its holdings in shares of Entera Bio by 2.4% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company's stock worth $781,000 after purchasing an additional 9,558 shares during the last quarter. 14.11% of the stock is owned by institutional investors and hedge funds.
Entera Bio Stock Performance
NASDAQ:ENTX traded down $0.05 during mid-day trading on Friday, hitting $1.73. The company's stock had a trading volume of 17,923 shares, compared to its average volume of 128,627. Entera Bio has a fifty-two week low of $0.52 and a fifty-two week high of $3.35. The stock has a fifty day moving average of $1.85 and a 200-day moving average of $1.91.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Entera Bio in a research report on Monday, November 11th.
Get Our Latest Stock Analysis on Entera Bio
Entera Bio Company Profile
(
Get Free Report)
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Entera Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.
While Entera Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
